Explore
Trendline
GSK Licenses siRNA Drug from China's SiranBio in $1 Billion Deal to Target Cardiometabolic Diseases
GSK Licenses siRNA Drug from China's SiranBio in $1 Billion Deal to Target Cardiometabolic Diseases
Read More
Trendline
Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments
Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments
Read More
Trendline
Vanda Pharmaceuticals Reports Q1 2026 Financial Results Highlighting Growth and New Product Launches
Vanda Pharmaceuticals Reports Q1 2026 Financial Results Highlighting Growth and New Product Launches
Read More
Trendline
EyePoint Pharmaceuticals Reports Q1 2026 Financial Results Amid Clinical Progress
EyePoint Pharmaceuticals Reports Q1 2026 Financial Results Amid Clinical Progress
Read More
Trendline
EyePoint Reports Q1 2026 Financial Results, Highlights Progress in Retinal Disease Trials
EyePoint Reports Q1 2026 Financial Results, Highlights Progress in Retinal Disease Trials
Read More
Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Read More
Trendline
Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark
Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark
Read More
Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Read More
Trendline
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results
Read More
Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Read More
Trendline
Pulmonx Corp Reports Decline in Q1 2026 Revenue Amid China Shipment Delays
Pulmonx Corp Reports Decline in Q1 2026 Revenue Amid China Shipment Delays
Read More
Trendline
Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market
Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market
Read More
